Biopharmaceutical company Ascendis Pharma A/S (ASND) is on the brink of a pivotal moment with its flagship candidate, TransCon CNP, as it undergoes priority review by the U.S. FDA for the treatment of achondroplasia in children. Mark your calendars for November 30, 2025, when the PDUFA decision is expected. This could meaningfully impact the company's valuation and strategic future.
Meanwhile, the significance continues across the Atlantic, as a parallel marketing application has been filed in Europe. The journey ahead for this groundbreaking program is shaping up to be both critical and promising!
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.